 International Business Times |
MannKind Moves Forward on Trials for Inhaled Insulin Treatment
Minyanville.com The company will study patients with type 2 diabetes in one trial and type 1 in the other. Type 2 diabetes is the most common and fastest-growing form of the disease and is blamed in part on the obesity epidemic in the US. Type 1 is often diagnosed in … MannKind shares soar after FDA clears trial for insulin drugCt Post MannKind Confirms Design of Pivotal StudiesMarketWatch (press release) MannKind finalizes design for insulin therapy trialsPharmaceutical Business Review Pharma Times all 33 news articles » |
More details can be found at www.diabeteshowto.com
Discussion
Comments are disallowed for this post.
Comments are closed.